jeudi 5 janvier 2017

Onco Actu du 5 janvier 2017


1. Biologie

Comprehensive study of esophageal cancer reveals several molecular subtypes, provides new insight into increasingly prevalent disease [Dana-Farber]

3.1 Tabac

Doctors urge Theresa May to publish anti-smoking strategy [The Guardian]

4.9 Dép., diag. & prono. - Sein

Biomarker tests in breast cancer: Decision on chemotherapy remains difficult [ecancer news]

5. Traitements

Little survival benefit and higher costs in advanced non-small cell lung cancer associated with new drugs [Colorado Cancer Blogs]

For Some Breast Cancer Survivors, Drug May Reduce Treatment-Related Joint Pain [NCI]

5.12 Immunothérapies

Cancers Evade Immunotherapy By 'Discarding the Evidence' of Tumor-Specific Mutations [Johns Hopkins]

Neon Therapeutics Hauls in $70M for Personalized Cancer Vaccines [Xconomy]

5.12.1 Immunothérapies - partenariats

MD Anderson and Affimed announce clinical immuno-oncology development collaboration [MD Anderson]

5.12.4 Immunothérapies - Essais

Lycera's double-action immuno-oncology drug starts trials [FierceBiotech]

5.2 Pharma

Infinity Pharma R&D Chief Adams Retires Amid Restructuring, Job Cuts [Xconomy]

Former Novartis pharmaceuticals chief David Epstein is going biotech [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

You Wouldn’t Be Lying About That, Would You? [In the Pipeline]

5.3.4 Traitements - AMM (FDA, EMA)

New FDA Drug Approvals: Breaking Down the Numbers [RAPS]

A Review of CDER’s Novel Drug Approvals for 2016 [FDA Voice]

6. Lutte contre les cancers

Combining health records and genome sequencing for precision medicine [PHG Foundation]


6.10.1 Politiques (USA)

Biden to tackle broad range of cancer issues, including drug prices, after leaving White House [Washington Post]

6.4 Médico-éco

As health care costs spiral higher, hospital price increases are flying under the radar [HealthNewsReview]